US2004018960A1PendingUtilityA1

Water soluble paclitaxel derivatives

65
Assignee: PG TXL CO LPPriority: Mar 12, 1996Filed: Jul 14, 2003Published: Jan 29, 2004
Est. expiryMar 12, 2016(expired)· nominal 20-yr term from priority
A61K 31/4375A61L 2300/416A61K 47/60A61K 47/645A61K 31/337A61L 31/10A61L 2300/606A61K 51/0497A61P 35/02A61K 41/0038C08G 73/1092A61K 38/13A61K 51/065A61K 47/59A61K 2123/00A61P 35/00A61K 47/547A61L 31/16A61K 2121/00A61P 35/04
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method for treating cancer in a subject, comprising administering to a subject having cancer a water soluble conjugate comprising camptothecin in combination with a platinum drug.  
     
     
         2 . The method of  claim 1 , wherein said water soluble conjugate comprises, wherein said water soluble conjugate comprises a water soluble polymer conjugated to said camptothecin.  
     
     
         3 . The method of  claim 2 , wherein said water soluble polymer is polyglutamate.  
     
     
         4 . The method of  claim 3 , wherein said polyglutamate is poly(1-glutamic acid).  
     
     
         5 . The method of  claim 4 , wherein said polyglutamic acid has a molecular weight of about 5000 to about 100,000 daltons.  
     
     
         6 . The method of  claim 5 , wherein polyglutamic acid has a molecular weight of about 20,000 to about 80,000 daltons.  
     
     
         7 . The method of  claim 6 , wherein polyglutamic acid has a molecular weight of about 25,000 to about 50,000 daltons.  
     
     
         8 . The method of  claim 7 , wherein said composition comprises from about 2% to about 35% by weight of camptothecin.  
     
     
         9 . The method of  claim 8 , wherein said composition comprises about 32% by weight of camptothecin.  
     
     
         10 . The method of  claim 9 , wherein said cancer is breast cancer, ovarian cancer, malignant melanoma, lung cancer, gastric cancer, prostate cancer, colon cancer, head and neck cancer, leukemia or Kaposi's sarcoma.  
     
     
         11 . The method of  claim 10 , wherein said cancer is ovarian cancer.  
     
     
         12 . The method of  claim 10 , wherein said cancer is lung cancer.  
     
     
         13 . The method of  claim 10 , wherein said cancer is colon cancer.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.